A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

NCT01652547 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Melanoma and Merkel Cell Carcinoma

Interventions

DRUG: Pasireotide sub-cutaneous formulation
DRUG: Pasireotide lon acting release formulation

Sponsor

Novartis Pharmaceuticals